# Most powerful obesity drug yet: People lost up to 25% of weight in trial

> **Open Intelligence Dossier** · First detected: 2026-09-29 23:40 UTC · Category: Business

## Executive Summary
Eli Lilly's experimental triple agonist drug retatrutide demonstrates significant weight loss and A1C reduction in recent clinical trials.

## Intelligence Brief
Recent coverage details clinical trial results for an experimental drug developed by Eli Lilly named retatrutide. According to reports from Reuters and corporate disclosures, the triple agonist medication delivered substantial weight loss outcomes and A1C reduction in trial participants. These outcomes highlight the compound&amp;#039;s potential therapeutic applications for individuals managing obesity alongside type 2 diabetes. Media reports emphasize the clinical mechanisms and performance metrics of the triple hormone receptor agonist.


Outlets such as Reuters focus on the specific trial data regarding weight reduction percentages among diabetes patients, while corporate statements from Eli Lilly underscore the drug&amp;#039;s dual efficacy in lowering A1C levels alongside reducing body mass. The coverage highlights the compound as an experimental treatment currently moving through testing phases, positioning it within a competitive pharmaceutical landscape targeting metabolic disorders and obesity management. This development arrives amid sustained global medical and commercial interest in advanced pharmacological treatments for obesity and type 2 diabetes. Future coverage will likely monitor the progression of retatrutide through its remaining clinical trial phases and regulatory review processes.


The provided reports do not yet specify final timelines for commercial availability, regulatory submission dates, or pricing details. Observers and market analysts will continue to track upcoming data releases from Eli Lilly to evaluate how the triple agonist compares against established treatments in large-scale patient populations.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Eli Lilly | Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxQZVEybVR5TEhfdXpyS29qaVM3RVBvcGY4eU1UcjdRRDJKTkRjV2F0S3p6UDFBLUVrc1J1REtGU25Tc0QzVkVydTdSZ1IyWHRCWDRBZjM5X0o1d21xSkpyQWJvWHhDNlYzMThBdlpsYkZWT1pVTUpEeTdJMDlVdm12em1QdUZXX2NIU3J0dU52QUhNNl9kOGkzc3ZMbTJXNXlfX3JybFhUZnNneTdQbnlUM0pzRWFwRlZ1OXBwc29ZR2Fldw?oc=5) |
| Reuters | Lilly's experimental drug cuts weight by 21% in diabetes trial | [Source Link](https://news.google.com/rss/articles/CBMiyAFBVV95cUxOdmJvRVgxMnhYOXRRX3pwUGtKYXZic2pPbnhZTGp5SzVHbDR3M1ZQdlRkTFc2eW1NNnh3bkduWTh1MExJTXB6dTRidXNjdVBCVHJZT3lsWXJ2TWluQ2h6Rm5kTUxadFB4RzB3cUUxWFNzVmlkcmp4WXdEb2RWYy1TZkJQOFVHbGY2RnJHOHhPbjBvdmNqeFNWYmFLVkM0SzFySmo4ZTRfZ1NvN0NzRVZlMENDNlNRSlF3Y0RiREo3MzBFSGxBdDRNaA?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-09-29/most-powerful-obesity-drug-yet-people-lost-up-to-25-of-weight-in-trial*
